. Author manuscript; available in PMC: 2010 Apr 1.

Published in final edited form as: Pharmacol Res. 2008 Dec 31;59(4):263–268. doi: 10.1016/j.phrs.2008.12.008

Table.

2 Effect of Ang-(1−7) on post-ischemic recovery in hemodynamics.

Groups studied	Coronary flow (ml min⁻¹)			Coronary vascular resistance (mmHg ml⁻¹ min⁻¹)
	Control	Reperfusion	%R	Control	Reperfusion	%R
1. WKY	10.2 ± 0.5	4.5 ± 0.5	44 ± 4	4.4 ± 0.4	21 ± 2	486 ± 19
2. SHR	8.0 ± 0.3	2.0 ± 0.4	25 ± 5^*	6.8 ± 0.4	43 ± 5	627 ± 48^*
3. SHR-Ang-(1−7)	10.5 ± 0.4	3.4 ± 0.2	33 ± 2^*,^†	5.5 ± 0.3	28 ± 2	529 ± 40^†
4. Diabetic SHR	5.5 ± 0.4	0.8 ± 0.2	14 ± 3^*,^†	9.0 ± 0.4	66 ± 3	739 ± 18^*,^†
5. Diabetic SHR + Ang-(1−7)	6.1 ± 0.1	1.3 ± 0.2	22 ± 3^*,^§	8.7 ± 0.2	60 ± 1	694 ± 13^*,^§
6. Diabetic SHR + A779	5.0 ± 0.3	0.2 ± 0.1	4 ± 2^*,^†,^§	14.0 ± 1.2	88 ± 4	789 ± 19^*,^†,^§
7. Diabetic SHR + captopril	7.2 ± 0.3	1.5 ± 0.1	21 ± 2^*,^§	7.2 ± 0.3	47 ± 4	656 ± 22^*,^§
8. Diabetic SHR + captopril + A779	5.3 ± 0.5	0.9 ± 0.2	16 ± 2^*,^†,^#	9.8 ± 0.5	72 ± 3	739 ± 10^*,^†,^#

The data were computed at baseline (control) and again after 40 min of ischemia and a 30-min reperfusion period, and expressed as mean ± SEM (N = 6). %R = % recovery (reperfusion/control).

Value significantly different from WKY, p < 0.05.

^†

Value significantly different from SHR, p < 0.05.

^§

Value significantly different from diabetic SHR, p < 0.05.

Value significantly different from diabetic SHR-captopril, p < 0.05.